ArticleAmerican journal of translational research2025
Delta/pre-radiomics based on enhanced CT predicts complete response in locally advanced esophageal squamous cell carcinoma.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study aimed to evaluate the effectiveness of neoadjuvant immunochemotherapy (NIC) in patients diagnosed with locally advanced esophageal squamous cell carcinoma (LAESCC), by assessing the performance of models that utilize enhanced computed tomography (CT) images at the pre, post, and delta/pre group stages.
methodsA total of 225 patients were included in our study and randomly divided into a training set (n = 157) and test set I (n = 68). In addition, we conducted a test set II involving 60 patients from another center. We obtained omics features from CT images before and after NIC. Then, the delta radiomics features were obtained by calculating the differences between the post and pre group features, which was then divided by the pre group features to obtain the delta/pre group. Imaging and clinicopathological data were collected in the two centers according to the same inclusion and exclusion criteria. The tumor regression grading (TRG) system was used according to the Japanese Esophageal Cancer (11th edition). Three sets of models were built and their performance was assessed using receiver operating characteristic (ROC) curve, confusion matrix, and calibration curve. The clinical utility of the model was evaluated through decision curve analysis and nomogram.
resultsThe area under the curve value of the delta/pre-radiomics (Rad) score model was 0.876 in the training set and 0.827 and 0.749 in the two test sets, which was significantly higher than that in the pre and post Rad score models. The radiomics nomogram was constructed using Rad scores derived from the post model, delta/pre model, Ki67, P53, and the pathological stage of lymph node after neoadjuvant therapy (ypN), demonstrating robust performance. The internal correction curve (apparent) and the external correction curve (bias-corrected) exhibited negligible deviations from the ideal curve, thereby demonstrating a high level of similarity.
conclusionNomogram, based on delta/pre-enhanced CT features and clinical risk indicators, is a non-invasive tool to predict therapeutic effects in patients with LAESCC after NIC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.